


Product Data Sheet

CPI-169

Cat. No.:	B4678
CAS No.:	1450655-76-1
Formula:	C ₂₇ H ₃₆ N ₄ O ₅ S
M.Wt:	528.66
Synonyms:	
Target:	Stem Cell
Pathway:	EZH2
Storage:	Store at -20°C



Solvent & Solubility

≥26.45 mg/mL in DMSO; insoluble in H₂O; ≥2.18 mg/mL in EtOH with gentle warming and ultrasonic

In Vitro

Preparing Stock Solutions	Mass		1mg	5mg	10mg
	Solvent	Concentration			
		1 mM	1.8916 mL	9.4579 mL	18.9157 mL
		5 mM	0.3783 mL	1.8916 mL	3.7831 mL
		10 mM	0.1892 mL	0.9458 mL	1.8916 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary

EZH2 inhibitor

IC₅₀ & Target

In Vitro

Cell Viability Assay

Cell Line: a variety of cell lines

Preparation method: The solubility of this compound in DMSO is >26.5mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Reacting conditions: N/A

	Applications:	In a variety of cell lines, CPI-169 inhibited the catalytic activity of PRC2 with IC50 value of < 1nM, decreased cellular levels of H3K27me3 with EC50 value of 70 nM, and triggered cell cycle arrest and apoptosis.
In Vivo	Animal experiment	
	Animal models:	EZH2 mutant KARPAS-422 diffuse large B-cell lymphoma (DLBCL) xenograft
	Dosage form:	200 mpk twice daily (BID); administered subcutaneously
	Applications:	In EZH2 mutant KARPAS-422 diffuse large B-cell lymphoma (DLBCL) xenograft, CPI-169 is well tolerated in mice with no observed toxic effect or body weight loss. CPI-169 treatment led to tumor growth inhibition (TGI) in a dose-dependent way and reduced the pharmacodynamic marker H3K27me3. The highest dose (200 mpk BID) led to complete tumor regression.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

1. Hamid Bolouri, Mary Young, et al. "Integrative network modeling reveals mechanisms underlying T cell exhaustion." bioRxiv. 2019 March 19.

See more customer validations on www.apexbt.com.

References


[1] Vidya Balasubramanian, Priya Iyer, Shilpi Arora, Patrick Troyer, Emmanuel Normant. Constellation Pharmaceuticals, Cambridge, MA. CPI-169, a novel and potent EZH2 inhibitor, synergizes with CHOP in vivo and achieves complete regression in lymphoma xenograft models.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APEX BIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.



APEx BIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

